BridgeMD
Phase II Randomized Clinical Trial of quinacrine versus metronidazole in resistant giardiasis in children: Quin4Kids
EU CTIS ID: 2023-510227-30-00
What this study is testing
To demonstrate the safety and non-inferior anti-giardia activity of oral quinacrine (QC) 6mg/kg/day administered every 8h for a period of 5 days compared to standard therapy (metronizadole high doses) in resistant intestinal giardiasis in children aged 1 to 18 years of age.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Children aged 1 to 18 years of age.
- Diagnosed with intestinal giardiasis.
- Informed consent/assent.
- Refractory to first line treatment
You likely can't join if
- History of allergy or previous positive skin-test reaction to any of the drug compounds included.
- Liver disease and/or liver enzymes > x3.
- Pregnant woman.
- Oral intolerance.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.